Insider Buying: Nasus Pharma (NYSEAMERICAN:NSRX) CEO Buys $20,305.00 in Stock

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman acquired 6,550 shares of Nasus Pharma stock in a transaction on Wednesday, June 17th. The shares were bought at an average cost of $3.10 per share, for a total transaction of $20,305.00. Following the completion of the purchase, the chief executive officer directly owned 163,541 shares of the company’s stock, valued at $506,977.10. The trade was a 4.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dan Benjamin Teleman also recently made the following trade(s):

• On Wednesday, April 22nd, Dan Benjamin Teleman acquired 2,900 shares of Nasus Pharma stock. The shares were bought at an average price of $3.76 per share, for a total transaction of $10,904.00.

Nasus Pharma Price Performance

NYSEAMERICAN:NSRX opened at $3.30 on Thursday. The company has a 50 day moving average of $3.00. Nasus Pharma Ltd. has a 1 year low of $1.98 and a 1 year high of $9.99.

Wall Street Analysts Forecast Growth

Separately, Citizens Jmp lowered their price target on Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $18.00.

About Nasus Pharma

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.